# US 2020/0347075 A1 · Bioactive conjugate, preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347075 A1
- Document ID: US20200347075A1
- Status: Published application
- Kind: A1
- Application number: 16/758,980
- Filed: 2018-12-10
- Published: 2020-11-05
- Earliest claimed: 2017-12-15
- Assignees: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Applicants: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Inventors: Jiaqiang CAI; Shuai SONG; Tongtong XUE; Liang XIAO; Hanwen DENG; Qiang TIAN; Jing WANG; Dengnian LIU; Liping Liu; Haimin YU; Zhouning YANG; Xu CAO; Guoqing ZHONG; Lichun WANG; Jingyi WANG
- Web page: https://patentgrep.com/patent/US20200347075A1

## CPC

- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6857: {the tumour determinant being from lung cancer cell}
- A61K 47/6885: {the conjugate or the polymer being a starburst, a dendrimer, a cascade}
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D 491/22: in which the condensed system contains four or more hetero rings
- C07K 5/06052: {Val-amino acid}
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

## Claims

### Claim at position 1

-91. (canceled)

### Claim 92

A compound as shown in formula (I) or a pharmaceutically acceptable salt thereof,
T-[L1-(L2)m1-(L3)m2-(L4)m3-E]-G formula (I)
wherein, T is a fragment of a bioactive molecule, preferably a fragment of a molecule with antitumor bioactivity;
L1 is selected from
an amino acid, a peptide composed of 2-10 amino acids, an oligosaccharide, —(CH2)t1—, —(CH2CH2O)t1—(CH2)t2—,
wherein each of R, R′, R1 and R2 is independently hydrogen, deuterium, halogen, a carboxylic acid group, a sulfonic acid group, cyano, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkyl substituted with cyano (e.g., —CH2CN), C1-6 alkoxy, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, 6-10 membered aryl or 5-12 membered heteroaryl, each Z1 is independently an amino acid or a peptide composed of 2-10 amino acids, each of t1 and t2 is independently 0, 1, 2, 3, 4, 5 or 6, each of x1 and x2 is independently 0, 1, 2, 3, 4, 5 or 6, each x3 is independently 0, 1, 2, 3 or 4, and L1 is bonded to T at the position 1 of L1;
L2 is selected from
an amino acid, a peptide composed of 2-10 amino acids, an oligosaccharide, —(CH2)t1—, —(CH2CH2O)t1—(CH2)t2—,
wherein each of R3, R4, R5 and R6 is independently selected from hydrogen, deuterium, halogen, a carboxylic acid group, a sulfonic acid group, CN, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkyl substituted with cyano, C1-6 alkoxy, C2-10 alkenyl, C2-10 alkynyl or C3-6 cycloalkyl or R5/R4, R5/R6 or R3/R5 together with the carbon atoms attached thereto form a 3-8 membered ring, each of t1 and t2 is independently 0, 1, 2, 3, 4, 5 or 6, each of y1 and y2 is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and L2 is bonded to L1 at the position 1 of L2;
L3 is selected from the following groups optionally substituted with one or more R7: 5-12 membered heteroarylene, amino, 3-8 membered cycloalkylene, 3-8 aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene, 6-12 membered fused heterocyclylene, 6-10 membered arylene or 3-8 membered cycloalkylene-W—; wherein W is oxygen or NR8, R7 is independently selected from hydrogen, deuterium, halogen, ═O, CN, carboxyl, sulfonic acid group, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkyl substituted with cyano, C1-6 alkoxy, C2-10 alkenyl or C2-10 alkynyl, R8 is independently selected from hydrogen, deuterium, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy or cyano C1-2 alkyl, and L3 is bonded to L2 at the position 1 of L3;
L4 is selected from
wherein Z5 is preferably selected from C2-6 alkynyl, C2-6 alkenyl, amido group, sulfuryl, sulfinyl, 6-10 membered arylene or 5-6 membered heteroarylene; Z2 is selected from C1-6 alkylene, C2-10 alkenylene, C2-10 alkynylene, C3-8 cycloalkylene, 6-10 membered arylene or 5-14 membered heteroarylene; R9 is selected from hydrogen or C1-6 alkyl; Z3 is absent or selected from C1-6 alkylene, halogenated C1-6 alkylene or C1-6 alkylene substituted with alkoxy; or R9 and Z3 together with nitrogen atom attached thereto form a 4-8 membered heterocyclyl; α is independently 0, 1, 2, 3,4, 5 or 6; and L4 is bonded to E at the position 2 of L4;
E is selected from the following groups optionally substituted with one or more R12: pyrimidylene, quinolylene or pyrrolo[2,3-d]pyrimidylene; wherein R12 is independently selected from hydrogen, deuterium, halogen, CN, nitro, C1-6 alkyl or halogenated C1-6 alkyl;
G is a leaving group for nucleophilic substitutions;
each of m1, m2, and m3 is independently 0, 1, 2, 3, 4,5, 6, 7, 8, 9 or 10.

### Claim 93 (depends on 92)

The compound or the pharmaceutically acceptable salt of claim 92, wherein,
L1 is selected from
Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, a peptide composed of 2-5 amino acids,
wherein each of R, R′, R1 and R2 is independently hydrogen, deuterium, C1-6 alkyl, C2-10 alkenyl, C2-10 alkynyl or C3-6 cycloalkyl, Z1 is Lys, Val, Cit, Phe, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Cit-Ala, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg or Ala-Ala-Asn, x1 is 0, 1, 2 or 3, and x3 is 0, 1, 2, 3 or 4;
preferably, L1 is selected from
Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Cit-Val, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn,
wherein each of R, R′ and R1 is independently hydrogen, deuterium, C1-6 alkyl, C2-10 alkenyl, C2-10 alkynyl or C3-6 cycloalkyl, Z1 is Lys, Val, Cit, Phe, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Cit-Ala, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg or Ala-Ala-Asn, and each of x1 and x3 is independently 0, 1, 2 or 3;
more preferably, L1 is selected from
Lys, Cit, Cit-Val, Val-Ala, Lys-Val or
wherein each of R, R′ and R1 is independently hydrogen, deuterium or C1-4 alkyl, Z1 is Lys, Cit, Cit-Val, Cit-Ala, Val-Ala or Lys-Val, and each of x1 and x3 is independently 0, 1 or 2;
more preferably, L1 is selected from
more preferably, L1 is selected from

### Claim 94 (depends on 92)

The compound or the pharmaceutically acceptable salt of claim 92, wherein,
L2 is selected from
Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, a peptide composed of 2-5 amino acids,
wherein each of R3, R4, R5 and R6 is independently selected from hydrogen, deuterium, halogen, a carboxylic acid group, a sulfonic acid group, CF3, CN, CH2CN, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl, C2-6 alkynyl or C3-6 cycloalkyl, each of y1 and y2 is independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and L2 is bonded to L1 at the position 1 of L2;
m1 is 0, 1, 2 or 3;
preferably, L2 is selected from
Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn,
wherein each of R3, R4, R5 and R6 is independently selected from hydrogen, deuterium, halogen, carboxylic acid group, sulfonic acid group, CF3, CN, CH2CN, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl, C2-6 alkynyl or C3-6 cycloalkyl, each of y1 and y2 is independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and L2 is bonded to L1 at the position 1 of L2;
m1 is 0, 1 or 2;
more preferably, L2 is selected from
wherein each of R3, R4, R5 and R6 is independently selected from hydrogen, deuterium or C1-4 alkyl, each of y1 and y2 is independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and L2 is bonded to L1 at the position 1 of L2;
m1 is 1;
more preferably, L2 is selected from
more preferably, L2 is selected from

### Claim 95 (depends on 92)

The compound or the pharmaceutically acceptable salt of claim 92, wherein,
L3 is selected from the following groups optionally substituted with one or more R7: 5-12 membered heteroarylene, amino, 3-8 membered cycloalkylene, 3-8 aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene, 6-12 membered fused heterocyclylene, 6-10 membered arylene or 3-8 membered cycloalkylene-W—; wherein W is oxygen or NR8, R7 is independently selected from hydrogen, deuterium, halogen, ═O, CF3, CN, CH2CN, carboxyl, sulfonic acid group, C1-4 alkyl, C1-4alkoxy, C2-6 alkenyl or C2-6 alkynyl; preferably, the 3-8 aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene or 6-12 membered fused heterocyclylene has one or more nitrogen atoms; preferably, the 3-8 membered aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene or 6-12 membered fused heterocyclylene has one or more quaternized nitrogen atoms; preferably, the 3-8 membered aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene or 6-12 membered fused heterocyclylene has one or more nitrogen atoms, and at least one nitrogen atom is substituted with ═O; R8 is independently selected from hydrogen, deuterium, C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl, C1-6 alkoxy or cyano C1-2 alkyl;
m2 is 0, 1, 2 or 3;
preferably, L3 is selected from the following groups optionally substituted with one or more R7: 5-10 membered heteroarylene, amino or 3-6 membered aliphatic heterocyclylene; wherein R7 is independently selected from hydrogen, deuterium, halogen, ═O, CF3, CN, CH2CN, carboxyl, sulfonic acid group, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl or C2-6 alkynyl; preferably, the 3-6 membered aliphatic heterocyclylene has one or more nitrogen atoms; preferably, the 3-6 membered aliphatic heterocyclylene has one or more quaternized nitrogen atoms; preferably, the 3-6 membered aliphatic heterocyclylene has one or more nitrogen atoms, and at least one nitrogen atom is substituted with ═O;
m2 is 0, 1 or 2;
more preferably, L3 is selected from 5-6 membered heteroarylene optionally substituted with one or more R7; wherein R7 is independently selected from hydrogen, deuterium, halogen, ═O, CF3, CN, CH2CN, carboxyl, sulfonic acid group, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl or C2-6 alkynyl;
m2 is 1;
more preferably, L3 is selected from the following groups optionally substituted with one or more R7: triazolylene, pyrazolylene, amino or N-methylpiperidylene; wherein R7 is independently selected from hydrogen, deuterium, halogen, ═O, CF3, CN, CH2CN, carboxyl, sulfonic acid group, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl or C2-6 alkynyl;
m2 is 0 or 1;
more preferably, L3 is selected from triazolylene.
m2 is 0 or 1.

### Claim 96 (depends on 92)

The compound or the pharmaceutically acceptable salt of claim 92, wherein L4 is selected from
wherein Z4 is 6-10 membered arylene or 5-6 membered heteroarylene; R10 is selected from hydrogen or C1-6 alkyl; Z2 is selected from C1-6 alkylene, C2-10 alkenylene, C2-10 alkynylene or C3-8 cycloalkylene; R9 is selected from hydrogen or C1-6 alkyl; Z3 is absent or selected from C1-6 alkylene; or R9 and Z3 together with the nitrogen atom attached thereto form a 4-8 membered heterocyclylene; α is independently 0, 1, 2, 3, 4, 5 or 6, and L4 is bonded to E at the position 2 of La;
m3 is 0, 1, 2 or 3;
preferably, L4 is selected from
Z4 is a benzene ring, and R10 is selected from hydrogen or C1-6 alkyl; Z2 is selected from C1-6 alkylene, C2-10 alkenylene, C2-10 alkynylene or C3-8 cycloalkylene; R9 is selected from hydrogen or C1-6 alkyl; Z3 is absent or selected from C1-6 alkylene or R9 and Z3 together with the nitrogen atom attached thereto form a 4-8 membered heterocyclylene; a is independently 0, 1, 2, 3, 4, 5 or 6, and L4 is bonded to E at the position 2 of La;
m3 is 0, 1, 2 or 3;
more preferably, L4 is selected from
and Z4 is 5-6 membered heteroarylene; R10 is selected from hydrogen or C1-6 alkyl; Z2 is selected from C1-6 alkylene, C2-10 alkenylene, C2-10 alkynylene or C3-8 cycloalkylene; R9 is selected from hydrogen or C1-6 alkyl; Z3 is absent or selected from C1-6 alkylene; or R9 and Z3 together with the nitrogen atom attached thereto form a 4-8 membered heterocyclylene; α is independently 0, 1, 2, 3,4, 5 or 6; and L4 is bonded to E at the position 2 of La;
m3 is 0, 1, 2 or 3;
more preferably, L4 is selected from
m3 is 1;
more preferably, L4 is selected from
m3 is 1;
more preferably, L4 is selected from
m3 is 1.

### Claim 97 (depends on 92)

The compound or the pharmaceutically acceptable salt of claim 92, wherein,
E is selected from pyrimidylene optionally substituted with one or more R12; wherein R12 is independently selected from hydrogen or deuterium.

### Claim 98 (depends on 92)

The compound or the pharmaceutically acceptable salt of claim 92, wherein,
G is selected from alkyl sulfonyl, halogen, OMs, OTs, OTf, nitro or the following groups optionally substituted with one or more R13: alkylthio, arylthio, heteroarylthio, alkyl sulfinyl, aryl sulfinyl, heteroaryl sulfinyl, aryl sulfonyl or heteroaryl sulfonyl; wherein R13 is independently selected from hydrogen, deuterium, halogen, CN, nitro, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 6-10 membered aryl or 5-12 membered heteroaryl;
preferably, G is selected from methylsulfonyl, F, Cl, Br, I, OMs, OTs, OTf, ethylsulfonyl, p-toluenesulfonyl or naphthalenesulfonyl;
more preferably, G is selected from methylsulfonyl, F, Cl, Br, OMs, OTs or p-toluenesulfonyl;
more preferably, G is selected from Cl or methylsulfonyl.

### Claim 99 (depends on 92)

The compound or the pharmaceutically acceptable salt of claim 92, wherein,
in
G is preferably methylsulfonyl, E is preferably pyrimidylene, m3 is 1;
preferably,
is:
(1)
wherein m4 is preferably an integer from 0 to 6, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring;
(2)
wherein m5 is preferably an integer from 0 to 6, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring;
(3)
wherein m6 is preferably an integer from 0 to 6, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring;
(4)
wherein m7 is an integer from 1 to 5, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring;
(5)
wherein m8 is an integer from 1 to 5, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring;
(6)
wherein m9 is an integer from 1 to 5, R13 is selected from hydrogen or C1-6 alkyl, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring;
(7)
wherein m10 is an integer from 0 to 6, and Z4 is selected from 5-6 membered heteroarylene; methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring;
(8)
Z4 is selected from pyridylene, pyrimidylene, pyrazolylene, thiazolylene, oxazolylene or triazolylene; methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring; or,
(9)
Z4 is selected from oxazolylene or thiazolylene, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring;
preferably,
is

### Claim 100 (depends on 92)

The compound or the pharmaceutically acceptable salt of claim 92, wherein -[L1-(L2)m1-(L3)m2-(L4)m3-E]-G is selected from the following fragments:

### Claim 101 (depends on 92)

The compound or the pharmaceutically acceptable salt of claim 92, wherein,
T is a fragment of a bioactive molecule, and the bioactive molecule is selected from a metal complex such as a platinum metal complex (e.g., oxaliplatin) or a gold metal complex; a glycopeptide antibiotic such as bleomycin or pingyangmycin; a DNA topoisomerase inhibitor such as a topoisomerase I inhibitor (e.g., camptothecin, hydroxycamptothecin, 9-aminocamptothecin, SN-38, irinotecan, topotecan, bellotencian or rubitecan) or a topoisomerase II inhibitor (e.g., actinomycin D, doxorubicin, duocarmycin, daunorubicin, mitoxantrone, podophyllotoxin or etoposide); a drug interfering with DNA synthesis, such as methotrexate, 5-fluorouracil, cytarabine, gemcitabine, mercaptopurine, pentostatin, fludarabine, cladribine or narabine; a drug acting on a structural protein, such as a tubulin inhibitor, a vinblastine alkaloid, a vincristine, vinblastine, paclitaxel, docetaxel or cabazitaxel; a tumor cell signaling pathway inhibitor such as a serine/threonine kinase inhibitor, a tyrosine kinase inhibitor, a aspartokinase inhibitor or a histidine kinase inhibitor; a proteasome inhibitor; a histone deaceylase inhibitor; a tumor angiogenesis inhibitor; a cyclin inhibitor; a maytansine derivative; a calicheamicin derivative; a auristatin derivative; a pyrrolobenzodiazepine dimers (PBD) derivative; melphalan; mitomycin C; or chlorambucil; or other active substances which inhibit the growth of tumor cells, promote the apoptosis or necrosis of tumor cells;
preferably, the bioactive molecule is selected from
wherein R14 is selected from acyl or sulfonyl, which is substituted with R15, and R15 is selected from C1-6 alkyl, halogenated C1-6 alkyl, 6-10 membered aryl or 5-12 membered heteroaryl; R16 is selected from hydrogen, deuterium, C1-6 alkyl, C1-6 alkyl substituted with R17, and R17 is selected from aryl or heteroaryl, including but not limited to phenyl and pyridyl, and m11 is selected from 0, 1, or 2;
preferably, the bioactive molecule is selected from
wherein R14 is selected from acyl or sulfonyl, which are substituted with R15, and R15 is selected from C1-6 alkyl, halogenated C1-6 alkyl, 6-10 membered aryl or 5-12 membered heteroaryl; R16 is selected from hydrogen, deuterium, C1-6 alkyl, C1-6 alkyl substituted with R17, and R17 is selected from aryl or heteroaryl, and m11 is selected from 0, 1 or 2;
preferably, the bioactive molecule is selected from
more preferably, the bioactive molecule is selected from
more preferably, the bioactive molecule is selected from
more preferably, the bioactive molecule is selected from
more preferably, the bioactive molecule is selected from

### Claim 102 (depends on 92)

The compound or the pharmaceutically acceptable salt of claim 92, wherein T is selected from
preferably, T is selected from
more preferably, T is selected from
more preferably, T is selected from
more preferably, T is

### Claim 103 (depends on 92)

The compound or the pharmaceutically acceptable salt of claim 92, wherein the compound is selected from
preferably, the compound is selected from

### Claim 104 (depends on 92)

A conjugate comprising a fragment of a bioactive molecule, a linker, and a targeting moiety, wherein the targeting moiety is linked to the linker via an active group (e.g., a thiol group) to form a conjugate; wherein the conjugate has a structure shown in formula (II):
{T-[L1-(L2)m1-(L3)m2-(L4)m3-E]}γ-A formula (II)
wherein, A is a targeting moiety (e.g., a small molecule ligand, a protein, a polypeptide or a non-protein reagent (e.g., saccharide, RNA or DNA)); γ is an integer or a decimal from 1 to 10; preferably, γ is an integer or a decimal from 5 to 8 (e.g., 5, 6, 7 or 8);
the rest groups are as defined in claim 92.

### Claim 105 (depends on 104)

The conjugate of claim 104, wherein,
a target of A is selected from epidermal growth factor, Trop-2, CD37, HER2, CD70, EGFRvIII, Mesothelin, Folate receptor1, Mucin 1, CD138, CD20, CD19, CD30, SLTRK6, Nectin 4, Tissue factor, Mucin16, Endothelin receptor, STEAP1, SLC39A6, Guanylylcyclase C, PSMA, CCD79b, CD22, Sodium phosphate cotransporter 2B, GPNMB, Trophoblast glycoprotein, AGS-16, EGFR, CD33, CD66e, CD74, CD56, PD-L1, TACSTD2, DR5, E16, 0772P, MPF, Napi3b, Sema 5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcRH2, NCA, MDP, IL20Rα, Brevican, EphB2R, ASLG659, PSCA, GEDA, BAFF-R, CD79a, CXCR5, HLA-DOB, P2X5, CD72, LY64, FcRH1, IRTA2, TENB2, integrin α5β6, α4β7, FGF2, FGFR2, Her3, CA6, DLL3, DLL4, P-cadherin, EpCAM, pCAD, CD223, LYPD3, LY6E, EFNA4, ROR1, SLITRK6, 5T4, ENPP3, Claudin18.2, BMPR1B, Tyro7, c-Met, ApoE, CD1 lc, CD40, CD45 (PTPRC), CD49D (ITGA4), CD80, CSF1R, CTSD, GZMB, Ly86, MS4A7, PIK3AP1, PIK3CD, CCR5, IFNG, IL10RA1, IL-6, ACTA2, COL7A1, LOX, LRRC15, MCPT8, MMP10, NOG, SERPINEI, STAT1, TGFBR1, CTSS, PGF, VEGFA, C1QA, C1QB, ANGPTL4, EGLN, EGLN3, BNIP3, AIF1, CCL5, CXCL10, CXCL11, IFI6, PLOD2, KISS1R, STC2, DDIT4, PFKFB3, PGK1, PDK1, AKR1C1, AKR1C2, CADM1, CDH11, COL6A3, CTGF, HMOX1, KRT33A, LUM, WNT5A, IGFBP3, MMP14, CDCP1, PDGFRA, TCF4, TGF, TGFB1, TGFB2, CD1 lb, ADGRE1, EMR2, TNFRSF21, UPK1B, TNFSF9, MMP16, MFI2, IGF-1R, RNF43, NaPi2b or BCMA;
or, A is a small molecule ligand such as a folic acid derivative, a glutamate urea derivative, a somatostatin derivative, an arylsulfonamide derivative (e.g., a carbonic anhydrase IX inhibitor), a polyene connecting two aliphatic indoles, a cyanine dye or IR-783 or a derivative thereof; preferably, A is selected from

### Claim 106 (depends on 104)

The conjugate of claim 104, wherein,
A is an antibody such as a monoclonal antibody or an antigen binding fragment thereof, wherein the monoclonal antibody or the antigen binding fragment thereof comprises Fab, Fab′, F(ab′)2, Fd, Fv, dAb, a complementary determinant fragment, a single chain antibody (e.g., scFv), a non-human antibody, a humanized antibody, a chimeric antibody, a completely humanized antibody, a probody, a bispecific antibody or a multispecific antibody;
preferably, A is an anti-Her 2 monoclonal antibody or an anti-Trop-2 monoclonal antibody, preferably, the anti-Trop-2 monoclonal antibody is selected from antibodies of Sacituzumab, M1, M2 or M3; preferably, the anti-Her 2 monoclonal antibody is selected from Trastuzumab or Pertuzumab;
wherein,
a heavy chain of the Sacituzumab has an amino acid sequence setting forth in SEQ ID No.: 19; and a light chain has an amino acid sequence setting forth in SEQ ID No.: 20;
a heavy chain variable region of antibody M1 has an amino acid sequence setting forth in SEQ ID No.: 11; and a light chain variable region has an amino acid sequence setting forth in SEQ ID No.: 12;
a heavy chain variable region of the antibody M2 has an amino acid sequence setting forth in SEQ ID No.: 13; and a light chain variable region has an amino acid sequence setting forth in SEQ ID No.: 14;
a heavy chain variable region of the antibody M3 has an amino acid sequence setting forth in SEQ ID No.: 15; and a light chain variable region has an amino acid sequence setting forth in SEQ ID No.: 16;
heavy chain constant regions of the antibodies M1, M2 and M3 have amino acid sequences setting forth in SEQ ID No.: 10; and light chain constant regions have amino acid sequences setting forth in SEQ ID No.: 9;
more preferably, A is an anti-Her 2 monoclonal antibody or an anti-Trop-2 monoclonal antibody, preferably, the anti-Trop-2 monoclonal antibody is selected from Sacituzumab, and the anti-Her 2 monoclonal antibody is selected from Trastuzumab or Pertuzumab.

### Claim 107 (depends on 104)

The conjugate of claim 104, wherein,
A is selected from a RGD peptide that recognizes cell surface integrin receptor; a growth factor that recognizes cell surface growth factor receptor, such as EGF, PDGF or VEGF; or a peptide capable of recognizing functional cell surface plasminogen activator, bombesin, bradykinin, somatostatin or prostate-specific membrane antigen receptor;
preferably, A is selected from a CD40 ligand, a CD30 ligand, an OX40 ligand, a PD-1 ligand, an ErbB ligand, a Her2 ligand, a TACSTD2 ligand or a DR5 ligand.

### Claim 108 (depends on 104)

The conjugate of claim 104, wherein, the conjugate is selected from:
wherein, γ is an integer or a decimal from 1 to 10, and mAb is an anti-Trop-2 monoclonal antibody or an anti-Her 2 monoclonal antibody; preferably, the anti-Trop-2 monoclonal antibody is selected from antibodies of Sacituzumab, M1, M2 or M3, and the anti-Her 2 monoclonal antibody is selected from Trastuzumab or Pertuzumab; preferably, γ is an integer or a decimal from 5 to 8 (e.g., 5, 6, 7 or 8);
preferably, the conjugate is selected from:
wherein, γ is an integer or a decimal from 1 to 10, and mAb is an anti-Trop-2 monoclonal antibody or an anti-Her 2 monoclonal antibody; preferably, the anti-Trop-2 monoclonal antibody is selected from Sacituzumab, and the anti-Her 2 monoclonal antibody is selected from Trastuzumab or Pertuzumab; preferably, γ is an integer or a decimal from 5 to 8 (e.g., 5, 6, 7 or 8).

### Claim 109 (depends on 104)

The conjugate of claim 104, wherein the conjugate is selected from:
wherein, A1 is Sacituzumab, and γ is an integer or a decimal from 1 to 10; preferably, γ is an integer or a decimal from 5 to 8;
preferably, the conjugate is selected from:
wherein, A1 is Sacituzumab, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8;
more preferably, the conjugate is selected from:
wherein, A1 is Sacituzumab, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.

### Claim 110 (depends on 104)

The conjugate of claim 104, wherein the conjugate is selected from:
wherein, A2 is Trastuzumab, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8;
preferably, the conjugate is selected from:
wherein, A2 is Trastuzumab, and γ is an integer or a decimal from 1 to 10; preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8;
more preferably, the conjugate is:
wherein A2 is Trastuzumab, and γ is an integer or a decimal from 1 to 10; preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.

### Claim 111 (depends on 104)

The conjugate of claim 104, wherein the conjugate is selected from:
wherein A3 is Pertuzumab, and γ is an integer or a decimal from 1 to 10; preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8;
preferably, the conjugate is selected from:
wherein A3 is Pertuzumab, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.

### Claim 112 (depends on 104)

The conjugate of claim 104, wherein the conjugate is selected from:
wherein, A4 is antibody M1, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8;
preferably, the conjugate is:
wherein A4 is antibody M1, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.

### Claim 113 (depends on 104)

The conjugate of claim 104, wherein the conjugate is selected from:
wherein, A5 is antibody M2, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8;
preferably, the conjugate is:
wherein, A5 is antibody M2, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.

### Claim 114 (depends on 104)

The conjugate of claim 104, wherein the conjugate is selected from:
wherein, A6 is antibody M3, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8;
preferably, the conjugate is:
wherein, A6 is antibody M3, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.

### Claim 115 (depends on 104)

A method for preparing the conjugate of claim 104 comprising a step of coupling the linker of the compound of formula (I) with an active group of the targeting moiety;
preferably, the method comprising a step of coupling the linker of the compound of formula (I) with an active group of the targeting moiety to form a C—S bond;
preferably, the targeting moiety of the conjugate is an anti-Her 2 monoclonal antibody or an anti-Trop-2 monoclonal antibody or an active fragment or mutant thereof; preferably, the anti-Trop-2 monoclonal antibody is selected from antibodies of Sacituzumab, M1, M2 or M3, and the anti-Her 2 monoclonal antibody is selected from Trastuzumab or Pertuzumab;
preferably, the targeting moiety of the conjugate is an anti-Her 2 monoclonal antibody or an anti-Trop-2 monoclonal antibody or an active fragment or mutant thereof; preferably, the anti-Trop-2 monoclonal antibody is selected from Sacituzumab, and the anti-Her 2 monoclonal antibody is selected from Trastuzumab or Pertuzumab;
preferably, the molar ratio of the targeting moiety of the conjugate to the compound of formula (I) is 1:(1-20); preferably, the coupling is carried out in water and/or an organic solvent; preferably, the organic solvent is selected from N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone, nitriles (e.g., acetonitrile), alcohols (e.g., methanol, ethanol) or any combination thereof;
preferably, the method further comprising a step of purifying a coupling product; preferably, the coupling product is purified by chromatography; preferably, the chromatography comprises one or more of ion exchange chromatography, hydrophobic chromatography, reversed phase chromatography or affinity chromatography.

### Claim 116 (depends on 104)

A pharmaceutical composition comprising the conjugate of claim 104, and one or more pharmaceutical excipients.

### Claim 117 (depends on 104)

A method of treating a disease associated with an abnormal cell activity (e.g., cancer), comprising a step of administering an effective amount of the conjugate of claim 104 to an individual in need thereof; preferably, the cancer is selected from a solid tumor or a non-solid tumor, such as esophageal cancer (e.g., esophageal adenocarcinoma, esophageal squamous cell carcinoma), a brain tumor, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer), squamous cell carcinoma, bladder cancer, stomach cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, non Hodgkin's lymphoma, central nervous system tumors (e.g., neuroglioma, glioblastoma multiforme, glioma or sarcoma), prostate cancer or thyroid cancer.

### Claim 118 (depends on 103, 104)

The conjugate of claim 104
wherein, A is a targeting moiety (e.g., a small molecule ligand, a protein, a polypeptide or a non-protein reagent (e.g., saccharide, RNA or DNA)); γ is an integer or a decimal from 1 to 10; preferably, γ is an integer or a decimal from 5 to 8 (e.g., 5, 6, 7 or 8);
the rest groups are as defined in claim 103.

### Claim 119 (depends on 108)

The pharmaceutical composition, comprising the conjugate of claim 108, and one or more pharmaceutical excipients.

### Claim 120 (depends on 108)

A method of treating a disease associated with an abnormal cell activity (e.g., cancer), comprising a step of administering an effective amount of the conjugate of claim 108 to an individual in need thereof; preferably, the cancer is selected from a solid tumor or a non-solid tumor, such as esophageal cancer (e.g., esophageal adenocarcinoma, esophageal squamous cell carcinoma), a brain tumor, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer), squamous cell carcinoma, bladder cancer, stomach cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, non Hodgkin's lymphoma, central nervous system tumors (e.g., neuroglioma, glioblastoma multiforme, glioma or sarcoma), prostate cancer or thyroid cancer.

### Claim 121 (depends on 116)

A method of treating a disease associated with an abnormal cell activity (e.g., cancer), comprising a step of administering an effective amount of the pharmaceutical composition of claim 116 to an individual in need thereof; preferably, the cancer is selected from a solid tumor or a non-solid tumor, such as esophageal cancer (e.g., esophageal adenocarcinoma, esophageal squamous cell carcinoma), a brain tumor, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer), squamous cell carcinoma, bladder cancer, stomach cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, non Hodgkin's lymphoma, central nervous system tumors (e.g., neuroglioma, glioblastoma multiforme, glioma or sarcoma), prostate cancer or thyroid cancer.
